Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Glipizide in T2DM on Metformin
NCT00094770Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change From Baseline in HbA1c at 52 weeks. Started Sep 2004; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00094770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094770.